Table 1.
Characteristics of 64 relapsed case subjects and 64 successfully treated matched control subjects with acute lymphoblastic leukemia selected from trials ALL-BFM 86 and ALL-BFM 90
| Cases (%) | Controls (%) | |
| Trial | ||
| ALL-BFM 86 | 35 (54.7) | 35 (54.7) |
| ALL-BFM 90 | 29 (45.3) | 29 (45.3) |
| Sex | ||
| Male | 42 (65.6) | 42 (65.6) |
| Female | 22 (34.4) | 22 (34.4) |
| Age (y) | ||
| <1 | 1 (1.6) | 1 (1.6) |
| 1-9 | 56 (87.5) | 56 (87.5) |
| 10-14 | 6 (9.4) | 7 (10.9) |
| 15-18 | 1 (1.6) | - |
| WBCa (103/μl) | ||
| <10 | 42 (65.6) | 41 (64.1) |
| 10-<50 | 21 (32.8) | 22 (34.4) |
| ≥ 50 | 1 (1.6) | 1 (1.6) |
| Immunophenotype | ||
| c-ALLb | 54 (84.4) | 54 (84.4) |
| pre-B-ALLc | 10 (15.6) | 10 (15.6) |
| Risk groupd | ||
| standard | 23 (35.9) | 23 (35.9) |
| intermediate | 41 (64.1) | 41 (64.1) |
| high | - | - |
| DNA indexe | ||
| <1.16 | 30 (46.9) | 30 (46.9) |
| ≥ 1.16 | 12 (18.8) | 7 (10.9) |
| not examined | 22 (34.4) | 27 (42.2) |
| Genotype | ||
| normal | 4 (6.3) | 10 (15.6) |
| 11q23 abberations | - | 1 (1.6) |
| t(1;19) | 1 (1.6) | - |
| t(9;22) | - | - |
| other | 15 (23.3) | 13 (20.3) |
| not examined | 44 (68.8) | 40 (62.5) |
a white blood cell count b common acute lymphoblastic leukemia c precursor B-cell acute lymphoblastic leukemia d therapy stratification in risk groups was mainly based on initial leukemic cell mass estimate and initial treatment response [16-18], e ratio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes